S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

$150.04
-2.57 (-1.68%)
(As of 03/4/2024 ET)
Today's Range
$149.89
$154.85
50-Day Range
$147.00
$198.20
52-Week Range
$143.52
$218.88
Volume
950,685 shs
Average Volume
969,584 shs
Market Capitalization
$18.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$216.12

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.58 Rating Score
Upside/​Downside
44.0% Upside
$216.12 Price Target
Short Interest
Healthy
3.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.67mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$5.85 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.73) to ($2.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

67th out of 960 stocks

Pharmaceutical Preparations Industry

25th out of 440 stocks


ALNY stock logo

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

ALNY Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ALNY Mar 2024 130.000 put
Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call
Alnylam Pharma (ALNY) was downgraded to a Hold Rating at Goldman Sachs
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/04/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$216.12
High Stock Price Target
$395.00
Low Stock Price Target
$161.00
Potential Upside/Downside
+44.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
19 Analysts

Profitability

Net Income
$-440,240,000.00
Pretax Margin
-23.71%

Debt

Sales & Book Value

Annual Sales
$1.83 billion
Book Value
($1.76) per share

Miscellaneous

Free Float
124,183,000
Market Cap
$18.90 billion
Optionable
Optionable
Beta
0.39

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Yvonne L. Greenstreet M.B.A. (Age 61)
    MBChB, CEO & Director
    Comp: $2.09M
  • Mr. Jeffrey V. Poulton M.B.A.Mr. Jeffrey V. Poulton M.B.A. (Age 56)
    CFO & Executive VP
    Comp: $972.35k
  • Dr. Akshay K. Vaishnaw M.D. (Age 61)
    Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board
    Comp: $1.24M
  • Dr. Pushkal P. Garg M.D. (Age 56)
    Chief Medical Officer and Executive VP of Development & Medical Affairs
    Comp: $1M
  • Ms. Indrani M. Lall Franchini J.D.Ms. Indrani M. Lall Franchini J.D. (Age 51)
    Executive VP & Secretary
    Comp: $958.96k
  • Mr. Timothy J. Maines
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 55)
    Senior VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom (Age 43)
    Senior VP of Investor Relations & Corporate Communications
  • Mr. Piyush Sharma J.D.
    Chief Ethics & Compliance Officer
  • Mr. Evan Lippman
    Chief Corporate Development & Strategy Officer














ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price target for 2024?

19 brokerages have issued 1-year price objectives for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $161.00 to $395.00. On average, they expect the company's stock price to reach $216.12 in the next twelve months. This suggests a possible upside of 44.0% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2024?

Alnylam Pharmaceuticals' stock was trading at $191.41 at the start of the year. Since then, ALNY stock has decreased by 21.6% and is now trading at $150.04.
View the best growth stocks for 2024 here
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The biopharmaceutical company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. The company's quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the business earned ($1.68) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (12.89%), Vanguard Group Inc. (9.52%), Baillie Gifford & Co. (5.55%), Dodge & Cox (2.92%), Capital International Investors (2.86%) and Price T Rowe Associates Inc. MD (2.78%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 3/5/2024 by MarketBeat.com Staff